<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01392807</url>
  </required_header>
  <id_info>
    <org_study_id>D3820C00010</org_study_id>
    <nct_id>NCT01392807</nct_id>
  </id_info>
  <brief_title>Open-label Study to Assess the Pharmacokinetics of NKTR-118 in Patients With Impaired Hepatic Function</brief_title>
  <official_title>An Open-label, Single-center Study to Assess the Pharmacokinetics of NKTR-118 in Patients With Impaired Hepatic Function and Subjects With Normal Hepatic Function Following Administration of a Single Dose of 25mg NKTR-118</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the pharmacokinetics of NKTR-118 in patients with
      impaired hepatic function versus subjects with normal hepatic function.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the pharmacokinetics of a single dose of NKTR-118 25 mg by assessment of area under the curve over the time (AUC) and maximum concentration (Cmax)</measure>
    <time_frame>Duration from predose day 1 to day 6.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To examine the safety and tolerability of a single oral dose of 25 mg NKTR-118 in patients with impaired hepatic function and in subjects with normal hepatic function by collecting adverse events.</measure>
    <time_frame>Duration from day -1 to follow up. ( Approximately 15-18 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To examine the safety and tolerability of a single oral dose of 25 mg NKTR-118 in patients with impaired hepatic function and in subjects with normal hepatic function by collecting vital signs</measure>
    <time_frame>Duration from day -1 to follow up. ( Approximately 15-18 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To examine the safety and tolerability of a single oral dose of 25 mg NKTR-118 in patients with impaired hepatic function by collecting safety blood samples</measure>
    <time_frame>Duration from day -1 to follow up. ( Approximately 15-18 days)</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Hepatic; Functional Disturbance</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Normal hepatic function, 25 mg NKTR-118 administered orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mild hepatic impairment, 25 mg NKTR-118 administered orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Moderate hepatic impairment, 25 mg NKTR-118 administered orally</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NKTR-118</intervention_name>
    <description>25 mg Oral tablets, single dose</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males or females aged 18 years or more with a weight of at least 50 kg and BMI between
             18 and 40 kg/m2, inclusive.

          -  Negative screen for human immunodeficiency virus (HIV)

          -  For subjects with normal hepatic function, negative results for serum hepatitis B
             (HBV) surface antigen, HCV antibody, and HIV

        Exclusion Criteria:

          -  Plasma or blood product donation within 1 month of screening or any blood
             donation/blood loss greater than 500 mL during the 3 months prior to screening.

          -  History of severe allergy/hypersensitivity or ongoing allergy/hypersensitivity

          -  Known or suspected history of drug/chemical abuse within the past 2 years as judged by
             the Investigator.

          -  Subjects with a history of surgery on the gastrointestinal tract.

          -  For patients with hepatic impairment, fluctuating or rapidly deteriorating hepatic
             function as indicated by clinical and/or laboratory signs of hepatic impairment (e.g.
             advanced ascites, infection of ascites, fever, or active gastrointestinal bleeding).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Sostek, MD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thomas Marbury, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Orlando Clinical Research Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bo Fransson, MD</last_name>
    <role>Study Chair</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&amp;studyid=1392&amp;filename=D3820C00010_Clinical_Study_Report_Synopsis.pdf</url>
    <description>D3820C00010 Clinical Study Report Synopsis.pdf</description>
  </link>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 8, 2011</study_first_submitted>
  <study_first_submitted_qc>July 12, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 13, 2011</study_first_posted>
  <last_update_submitted>October 13, 2014</last_update_submitted>
  <last_update_submitted_qc>October 13, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 15, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase 1</keyword>
  <keyword>volunteers with hepatic impairment</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>NKTR-118</keyword>
  <keyword>Child-Pugh scale</keyword>
  <keyword>AUC</keyword>
  <keyword>Cmax</keyword>
  <keyword>tmax</keyword>
  <keyword>t1/2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pathologic Processes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naloxegol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

